Synairgen (LON:SNG) Hits New 52-Week Low – Here’s What Happened

Synairgen plc (LON:SNG)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as GBX 1.71 ($0.02) and last traded at GBX 2.12 ($0.03), with a volume of 669799 shares changing hands. The stock had previously closed at GBX 2.06 ($0.03).

Synairgen Stock Up 3.2 %

The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35. The firm’s 50 day moving average is GBX 3.06 and its two-hundred day moving average is GBX 3.75. The firm has a market capitalization of £4.27 million, a P/E ratio of -70.67 and a beta of -2.23.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).